Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Kalafo ea Alopecia e boloka 80% ea moriri

ngotsoeng ke mohlophisi

Batho ba baholo ba nang le matla alopecia areata (AA) ea ileng a nka OLUMIANT® (baricitinib) o ile a finyella sekoahelo se seholo sa letlalo, lintši le moriri oa lintši 'me hoo e batlang e le 75% ea ba ileng ba arabela OLUMIANT 4-mg ba fihletse 90% ho koahela letlalo ka libeke tsa 52, Eli Lilly le Company le Incyte ba phatlalalitse kajeno. Sebokeng sa Selemo le Selemo sa American Academy of Dermatology (AAD). Ka Hlakola 2022, US Food and Drug Administration (FDA) e ile ea fana ka tlhahlobo ea mantlha bakeng sa OLUMIANT ho AA e matla joalo ka moriana o ka bang teng oa lefu la pele. Lilly o lebelletse liqeto tsa taolo ho la US, European Union le Japane ka 2022.

Tlhahlobong e kopaneng ea libeke tse 52, bakuli ba maemong a mantlha ba ne ba e-na le Bohloko bo bolelang Sesebelisoa sa Alopecia (SALT) palo ea 85.5 (85.5% ho lahleheloa ke moriri oa hlooho, kapa 14.5% ho koahela moriri oa hlooho); AA e matla e hlalosoa e le ho ba le lintlha tsa SALT ≥50 (≥50% tahlehelo ea moriri oa hlooho). Qalong, 69.4% le 57.9% ba ne ba e-na le moriri o moholo oa lintši le moriri oa moriri, ka ho latellana, joalokaha ho hlalosoa ke lintlha tsa Clinician-Reported Outcome (ClinRO) ≥2. Kakaretso ea lilemo tsa bakuli e ne e le lilemo tse 37.6, 'me moriri o qala ho lahleheloa ke lilemo tse 25 le lilemo tse 12.2 ho tloha ha matšoao a qala.

Har'a bakuli ba ileng ba nka OLUMIANT 4-mg, ba babeli ho ba bahlano (39.0%, n = 201 / 515) ba fihletse kholo ea bohlokoa ea moriri oa letlalo la hlooho, e hlalosoang e le lintlha tsa SALT ≤20, kapa 80% kapa ho feta ho koahela moriri oa hlooho, le hoo e batlang e le tse tharo ho tsoa. ho ba bane ho bakuli bao (74.1%, n = 149 / 201) le bona ba fihletse lintlha tsa SALT ≤10, kapa 90% ho koahela moriri, libeke tsa 52. Ka lehlakoreng le leng, bakuli ba fetang ba babeli ho ba bahlano ba nang le lintlha tsa motheo tsa ClinRO ≥2 (lintši: 44.1%, n = 154/349; eyelash: 45.3%, n = 139/307) e bone ho tsosolosoa ka ho feletseng kapa ho tsosolosa ka likheo tse fokolang ka har'a lintši le lintši. moriri.

Har'a bakuli ba ileng ba nka OLUMIANT 2-mg, ba fetang a le mong ho ba bahlano (22.6%, n = 77/340) ba fihletse ts'ebetso ea bohlokoa ea moriri oa letlalo la hlooho 'me ba babeli ho ba bararo ba bakuli bao (67.5%, n = 52/77) ba fihletse 90. % kapa ho feta ha moriri o koahela libeke tse 52. Ka lehlakoreng le leng, bakuli ba fetang a le mong ho ba bahlano le a le mong ho ba bane, ka ho latellana (lintši: 22.9%, n = 55/240; eyelash: 25.5%, n = 51/200), e bone ho tsosolosoa ka ho feletseng kapa ho tsosolosa ka likheo tse fokolang ka har'a lintši le lintši. moriri.

Litlhahlobo tsena tse kopaneng tsa libeke tse 52 li bonts'a ntlafatso e tsoelang pele ea letlalo la hlooho, lintši le ho hola hape ha moriri oa lintshi ho tsoa ho liphetho tsa libeke tse 36 tse phatlalalitsoeng kajeno ho New England Journal of Medicine le ho hlahisoa ho 2021 European Academy of Dermatology and Venereology (EADV) Congress.

“Ho sa tsotellehe hore na batho ba tšoeroeng ke lefu la alopecia areata ba lahleheloa ke moriri oohle ’meleng oa bona kapa mafatla ’me ba haelloa ke lintši kapa lintši, lefu lena la autoimmune le ka baka tšenyo e khōlō. Lefu lena le ama batho ba lilemo tsohle, "ho boletse Brett King, MD, Ph.D., FAAD, motlatsi oa moprofesa oa dermatology Yale School of Medicine le mongoli ea ka sehloohong oa litlhahlobo tsena. "Ka 2022, OLUMIANT e ka ba moriana oa pele o kileng oa amoheloa ho alafa batho ba baholo ba nang le alopecia areata. Hoa hlolla hore hoo e batlang e le 40% ea bakuli ba OLUMIANT 4-mg, bao kaofela ha bona ba qalileng bonyane 50% ea tahlehelo ea moriri oa hlooho, ba nang le moriri o feletseng kapa o batlang o le o feletseng, 'me ntlafatso e tšoanang e ile ea finyelloa har'a bakuli ba nang le lintši tse kholo kapa lintši. ho kenya letsoho. ”

Ha ho hlahlojoa OLUMIANT 4-mg le 2-mg ts'ireletseho ea nako e telele, litekanyetso tsa liketsahalo tse mpe tse tlalehiloeng khafetsa ho fihlela libeke tse 52 (ho pepeseha ha libeke tse 56) li ne li lumellana le nako ea libeke tse 36, tse laoloang ke placebo 'me li kenyelletsa phefumoloho e phahameng. tšoaetso ea pampitšana, hlooho e opang, makhopho, tšoaetso ea moroto le ho eketseha ha matšoao a mali a amanang le mesifa. Ho ne ho se na matšoao a macha a tšireletso.

“Boitsebiso ba nako e telele ba tšebetso ea OLUMIANT bo senola ho mela hape ho hoholo ha moriri oa letlalo la hlooho, lintši le lintši ’me re thabisoa ke seo liphello tsena li ka se bolelang ho bakuli. Lintlha tsa rona tsa polokeho ea alopecia areata li eketsa bopaki bo bong ho e 'ngoe ea lihlopha tse kholo ka ho fetisisa le tse telele ka ho fetisisa tsa tšireletso sehlopheng sa JAK inhibitor, ho kenyelletsa le lilemo tse robong le lilemo tse 19,000 tsa mokuli ho pholletsa le lenaneo la rona, "ho boletse Lotus Mallbris, MD, Ph.D., motlatsi oa mopresidente. ea nts'etsopele ea immunology ea lefats'e le litaba tsa bongaka ho Lilly. "Re thabile haholo hore OLUMIANT e kanna ea ba moriana oa pele oa lefu o amohetsoeng selemong sena bakeng sa batho ba baholo ba nang le alopecia areata e matla."

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...